Elizabeth M. Gore, MD

Publications

• Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study.

  (Eldridge RC, Pugh SL, Trotti A, Hu K, Spencer S, Yom SS, Rosenthal D, Read N, Desai A, Gore E, Shenouda G, Mishra MV, Bruner D, Xiao C.) Head Neck. 2019 11;41(11):3924-3932 PMID: 31435980 PMCID: PMC6865821 SCOPUS ID: 2-s2.0-85071015198 08/23/2019

• Dosimetric Predictors of Cardiotoxicity in Thoracic Radiotherapy for Lung Cancer.

  (Borkenhagen JF, Bergom C, Rapp CT, Klawikowski SJ, Rein LE, Gore EM.) Clin Lung Cancer. 2019 Nov;20(6):435-441 PMID: 31303452 SCOPUS ID: 2-s2.0-85068540623 07/16/2019

• Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.

  (Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM.) Radiother Oncol. 2019 06;135:19-24 PMID: 31015166 PMCID: PMC6582638 SCOPUS ID: 2-s2.0-85062352777 04/25/2019

• Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.

  (Sun A, Hu C, Wong SJ, Gore E, Videtic G, Dutta S, Suntharalingam M, Chen Y, Gaspar LE, Choy H.) JAMA Oncol. 2019 Jun 01;5(6):847-855 PMID: 30869743 PMCID: PMC6459052 SCOPUS ID: 2-s2.0-85062993057 03/15/2019

• Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

  (Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.) Lancet Oncol. 2018 11;19(11):1504-1515 PMID: 30316827 PMCID: PMC6540797 SCOPUS ID: 2-s2.0-85057161270 10/15/2018

• Feasibility of real-time lung tumor motion monitoring using intrafractional ultrasound and kV cone beam projection images.

  (Mostafaei F, Tai A, Gore E, Johnstone C, Haase W, Ehlers C, Cooper DT, Lachaine M, Li XA.) Med Phys. 2018 Oct;45(10):4619-4626 PMID: 30047160 SCOPUS ID: 2-s2.0-85052460630 07/27/2018

• Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

  (Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H.) JAMA Oncol. 2018 09 01;4(9):1263-1266 PMID: 29852037 PMCID: PMC6117102 SCOPUS ID: 2-s2.0-85050069518 06/01/2018

• An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy.

  (Konski A, Bhargavan M, Owen J, Komaki R, Langer CJ, Gore E, Paulus R, Choy H, Bruner DW, Curran WJ.) J Radiat Oncol. 2018 Jun;7(2):195-201 PMID: 30559923 PMCID: PMC6294122 12/19/2018

• Current Predictive Indices and Nomograms To Enable Personalization of Radiation Therapy for Patients With Secondary Malignant Neoplasms of the Central Nervous System: A Review.

  (Gilbride L, Siker M, Bovi J, Gore E, Schultz C, Hall WA.) Neurosurgery. 2018 05 01;82(5):595-603 PMID: 29669114 SCOPUS ID: 2-s2.0-85068839760 04/19/2018

• Select Patients With Limited Extensive-Stage Small Cell Lung Cancer Should Be Treated Aggressively.

  (Gore EM.) Int J Radiat Oncol Biol Phys. 2018 05 01;101(1):6-7 PMID: 29619978 SCOPUS ID: 2-s2.0-85044602808 04/06/2018

• Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

  (Nichols RC, Hu C, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Gore EM, Balogh AG, McGowan D, Michalski J, Raben A, Rudoler S, Jones CU, Sandler H.) Adv Radiat Oncol. 2017 Oct-Dec;2(4):608-614 PMID: 29204528 PMCID: PMC5707413 12/06/2017

• Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology Study

  (Eldridge RC, Pugh SL, Trotti A, Hu K, Spencer S, Yom S, Rosenthal D, Read N, Desai A, Gore E, Shenouda G, Mishra MV, Bruner D, Xiao C.) Head and Neck. 2019 SCOPUS ID: 2-s2.0-85071015198 01/01/2019